EntreMed Commences Leukemia Clinical Trial for MKC-1 in Canada

EntreMed Commences Leukemia Clinical Trial for MKC-1 in Canada: "ROCKVILLE, Md., July 24 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1 study of MKC-1 in leukemia patients at the Princess Margaret Hospital, University Health Network (UHN), Toronto, Canada. Dr. Karen Yee, Assistant Professor, University of Toronto, is the principal investigator for the clinical trial. EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the clinical trial in leukemia patients. A Canadian Clinical Trial Application (CTA) is similar to a United States (US) Investigational New Drug (IND) application."